Parallel session 10.00 - 12.00

Adapting and Reshaping Medicine for an Ageing Population

Advances in technology and medicines have constantly increased our life expectancy over the past century. By 2050, it is expected that almost 28% of Europe’s population will be over 65 years of age. Unfortunately, age comes at a cost, as chronic diseases related to advancing age become increasingly prevalent. Aging is the single largest risk factor for stroke, heart attacks, cancers, diabetes, and most other chronic diseases.

Older people face a multitude of challenges when maintaining their health. For example, they are more vulnerable to infectious diseases because their immune systems become weaker with age. Frail, elderly patients are often multimorbid, and are faced with polypharmacy problems. Moreover, older patients are known to be less responsive to drug treatments, chemotherapies, and organ or stem cell transplantation. In order to meet the needs of this important group of patients, our current practices need to be adapted and reshaped so that they also consider the frail and aging population.

How can we adjust our current practices to meet the needs of the elderly? Drug discovery and development, as well as the approval and use of medicines, need to become age appropriate. This challenge can only be addressed using a multidisciplinary and holistic approach, with all different stakeholders involved.


  • Dr. Paul Jansen, UMC Utrecht, Ephor (Expertisecentrum PHarmacotherapie bij OudeRen)
  • Prof. Sven Stegemann, President Geriatric Medicine Society, Professor for Patient Centric Drug Development and Manufacturing at Graz University of Technology
  • More speakers to be announced


back to program